GERN stock information

Sector:

Healthcare

Description:

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation website

Current Price

$3.60

RSI

87.60

Market Capitalization:

508.7M

Beta:

1.075

Volume:

16,831,874

Analyst Target Price:

$ 4.2

Economiic Fair Price:

Earnings DateNovember 03, 2022

Report DateNovember 07, 2022

QuarterQ3

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash

Debt

EPS-0.332

Profit MarginN/A

Revenue Per Share TTM0.001

Return On Equity TTM-0.561

YoY Revenue Growth (TTM)

527.62 %

YoY Pre Tax Income Growth (TTM)

-22.90 %

YoY Free Cash Flow (TTM)

-42.81 %

QoQ Revenue Growth

172.48 %

QoQ Pre Tax Income Growth

-53.77 %

QoQ Free Cash Flow Growth

-29.73 %

2021 Revenue

$ 1.4M

450.59 %

2020 Revenue

$ 253K

-45.00 %

2019 Revenue

$ 460K

-56.85 %

2018 Revenue

$ 1.1M

0.09 %

2017 Revenue

$ 1.1M

-82.72 %

2016 Revenue

$ 6.2M

2021 Free Cash Flow

$ -95.8M

-42.82 %

2020 Free Cash Flow

$ -67.1M

-51.56 %

2019 Free Cash Flow

$ -44.2M

-110.43 %

2018 Free Cash Flow

$ -21M

-2.28 %

2017 Free Cash Flow

$ -20.6M

-11.56 %

2016 Free Cash Flow

$ -18.4M

2021 Pre Tax Income

$ -116.1M

-53.55 %

2020 Pre Tax Income

$ -75.6M

-10.31 %

2019 Pre Tax Income

$ -68.5M

-153.72 %

2018 Pre Tax Income

$ -27M

3.22 %

2017 Pre Tax Income

$ -27.9M

5.49 %

2016 Pre Tax Income

$ -29.5M

Geron Corporation(GERN)